Freeline Therapeutics to Host Second Quarter 2023 Financial ... - Marketscreener.com
| TNG Stock | EUR 0.73 0.04 5.19% |
About 61% of Transgene's investor base is looking to short. The analysis of current outlook of investing in Transgene SA suggests that many traders are alarmed regarding Transgene's prospects. The current market sentiment, together with Transgene's historical and current headlines, can help investors time the market. In addition, many technical investors use Transgene SA stock news signals to limit their universe of possible portfolio assets.
Transgene |
Freeline Therapeutics to Host Second Quarter 2023 Financial ... Marketscreener.com
Read at news.google.com
 |
Transgene Fundamental Analysis
We analyze Transgene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Transgene is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Transgene SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Transgene stock to make a market-neutral strategy. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics with similar companies.
Peers
Transgene Related Equities
| IPH | Innate Pharma | 22.58 | ||||
| AB | AB Science | 2.25 | ||||
| GNFT | Genfit | 1.40 | ||||
| NANO | Nanobiotix | 2.13 |
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |